(Reuters) — Fitbit is developing a method to detect irregular heart rhythm in time through a partnership with Bristol-Myers Squibb-Pfizer Alliance, as the wearable device maker looks to match a feature available on rival Apple’s Watch.
Fitbit has been pushing deeper into the healthcare space and in August teamed up with the Singapore government to provide fitness trackers and services in a health program that the company said could reach up to 1 million users.
Under Thursday’s deal, the company’s devices will carry software that will help detect atrial fibrillation — the most common type of irregular heartbeat — after approval from the U.S. Food and Drug Administration.
Atrial fibrillation is a condition associated with irregular heart rhythm that increases the risk of stroke and is usually prevalent among people above 65 years of age.
June 5th: The AI Audit in NYC
Join us next week in NYC to engage with top executive leaders, delving into strategies for auditing AI models to ensure fairness, optimal performance, and ethical compliance across diverse organizations. Secure your attendance for this exclusive invite-only event.
About 2.7 million to 6 million people suffer from the condition in the United States, according to the Center for Disease Control and Prevention.
(Reporting by Ayanti Bera in Bengaluru; Editing by Sriraj Kalluvila)
